PathoVax

Biotechnology, Clinical Trials, Health Care
Founded in 2014-01-01
Baltimore, Maryland, United States
http://www.pathovax.com/
For Profit

About PathoVax

PathoVax is a biotech start-up from Johns Hopkins commercializing RGVax, the world’s first low-cost Human Papillomavirus (HPV) vaccine targeting all clinically relevant types. Current vaccines target some cancer-causing HPVs and only focus on sexual transmitted types, resulting in low uptake due to the incomplete coverage and social stigma. Established animal studies have confirmed RGVax’s protection against all 15 oncogenic types and the added coverage against skin HPVs positions RGVax as a childhood vaccine, allowing unrivalled early market entry in a segment with superior uptake.

Company Metrics

  • Employees: 1-10
  • Monthly Visits: None
  • Tech Stack: 8 active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 5975000 USD
  • Last Funding: 2750000 USD (Venture - Series Unknown)
  • Funding Status:

Technology Stack

PathoVax actively uses 8 products in their tech stack.

Market Presence

Industries: Biotechnology, Clinical Trials, Health Care

Headquarters: Baltimore, Maryland, United States